GSK and Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted the New Drug Application for bepirovirsen and granted it Priority Review status, with a PDUFA goal date of October 26, 2026. The FDA also awarded the drug Breakthrough Therapy designation, a designation that provides enhanced guidance and more frequent interactions with the agency to accelerate development.
Bepirovirsen is an antisense oligonucleotide that targets hepatitis B virus RNA. The drug was co‑developed by GSK and Ionis and is supported by the Phase III B‑Well 1 and B‑Well 2 trials, which demonstrated functional cure rates—defined as sustained loss of hepatitis B surface antigen and undetectable viral DNA—significantly higher than those seen with current nucleos(t)ide analogues. The trials also confirmed a favorable safety profile.
Chronic hepatitis B infects more than 250 million people worldwide and current standard therapies require lifelong treatment with functional cure rates of only about 1 %. A functional cure would represent a paradigm shift, potentially eliminating the need for ongoing therapy and reducing long‑term complications such as cirrhosis and hepatocellular carcinoma.
For GSK, the regulatory milestone expands its specialty medicines portfolio into a high‑unmet‑need area and strengthens the company’s pipeline narrative. The designation signals strong confidence from the FDA in the clinical data and may enhance investor perception of GSK’s ability to deliver breakthrough therapies in infectious diseases.
Ionis stands to receive milestone payments and future royalties once the drug is approved, reinforcing the value of its antisense platform and its partnership model with GSK.
GSK’s leadership highlighted the company’s focus on “advanced technologies and a growing R&D pipeline” and emphasized that the company’s “streamlined focus on biopharma” positions it well for long‑term growth. The company reiterated its commitment to addressing unmet medical needs in infectious diseases, including chronic hepatitis B.
revised_sentiment_rating":6}]}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.